| aGLP-1 | Indicated in the treatment of obesity | Indicated in type 2 diabetes |
| WEGOVY, SAXENDA | X | |
| MOUNJARO | X | X |
| OZEMPIC, TRULICITY, VICTOZA, XULTOPHY, BYETTA | X |
aGLP-1 indicated in the treatment of obesity
The initial prescription of aGLP-1 indicated in the treatment of obesity (WEGOVY, SAXENDA and MOUNJARO) must be carried out by a doctor specializing in endocrinology-diabetology-nutrition or competent in nutrition (i.e. holder of a DESC, an FST or a nutrition VAE). Renewals can be carried out by any doctor.
Doctors are also asked to comply with the HAS care pathway: prescribe aGLP-1 indicated in the treatment of obesity to patients with an initial body mass index (BMI) greater than or equal to 35 kg/m2aged under 65.
| These medications should only be used as a second line, in the event of failure of nutritional support in combination with a hypocaloric diet and physical activity. |
New aGLP-1, indicated in the treatment of obesity and type 2 diabetes
The drug MOUNJARO (tirzepatide) has been marketed since November 2024 in France, at a price freely set by the laboratory (not reimbursed). Agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), it is indicated in the treatment of obesity and type 2 diabetes.
Whatever the indication, this medicine is subject to the restricted prescription and supply conditions for aGLP-1 indicated in the treatment of obesity.
aGLP-1 indicated only in type 2 diabetes
The other aGLP-1 available today in France and indicated in type 2 diabetes only (OZEMPIC, TRULICITY, VICTOZA, XULTOPHY and BYETTA) are not subject to these restricted prescription conditions.
Source: ANSM news from 08/10/2024, updated on 13/11/2024
Health
